BSECompany Update31 Jul 2026 · 31 Jul 2026, 05:03 pm

Please find attached

India Glycols Ltd · 500201

✦ AI SummaryMgmt Change

India Glycols Ltd has transferred Shri Akshay Bansal, Head- Sales & Marketing of Ennature Biopharma Division, to Ennature Bio Pharma Limited, a wholly owned subsidiary, and he has been appointed as Additional Director (Executive Director) & Key Managerial Personnel of EBL.

Analysis Scores

Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

India Glycols Ltd - 500201 - Material Update In Connection With Ennature Bio Pharma Limited With Reference To Observation Letter No. NSE/LIST/48932 Dated 17Th November, 2025 And No. DCS/AMAL/TS/R37/3905/2025-26 Dated 19Th November, 2025 ("Observation Letters"), Issued By The National Stock Exchange Of India Limited And BSE Limited (Collectively The "Stock Exchanges"), Respectively, Received In Relation To The Scheme Of Arrangement.

Attachments (1)

📄

76102106-1e89-4b41-a805-c0fbeed38435.pdf

pdf

Download →
View document text
IGL/SE/2026-27/32 31st July, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (East), Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub.: i.) Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 : Update on Senior Managerial Personnel; and, ii.) Material Update in connection with Ennature Bio Pharma Limited with reference to Observation letter no. NSE/LIST/48932 dated 17th November, 2025 and no. DCS/AMAL/TS/R37/3905/2025-26 dated 19th November, 2025 ("Observation Letters"), issued by the National Stock Exchange of India Limited and BSE Limited (collectively the "Stock Exchanges"), respectively, received in relation to the Scheme of Arrangement. i. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) read with Para A of Part A of Schedule III and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 (as amended)(“SEBI Master Circular”), we wish to inform you that the Company has transferred Shri Akshay Bansal, Head- Sales & Marketing of Ennature Biopharma Division, a Senior Managerial Personnel (“SMP”) to Ennature Bio Pharma Limited (“EBL”), a wholly owned subsidiary of the Company, and consequently, he ceased to be a SMP of the Company from the close of business hours on 30th July, 2026. As required under SEBI Listing Regulations read with the SEBI Master Circular , the details are provided under Annexure A. ii. We would like to further inform you that EBL, through its letter dated 31st July, 2026 has communicated to the Company as a material event update that Shri Akshay Bansal (DIN:11836049) has been appointed as Additional Director (Executive Director) & Key Managerial Personnel (KMP) of EBL, which is enclosed herein as Annexure B. This disclosure is being made in respect of EBL, pursuant to the requirement in the Observation Letters and the SEBI Master Circular. Thanking you, Yours truly, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a ANNEXURE A Sr Particulars Details 1 Reason for change Shri Akshay Bansal (Senior Management Personnel) of (appointment, resignation, the Company has been transferred to Ennature Bio removal, death or Pharma Limited (“EBL”), a wholly owned subsidiary of the otherwise) Company. Consequently, he ceased to be the Senior Management Personnel of the Company from the close of business hours on 30th July, 2026. 2 Date of appointment and Not Applicable term of appointment 3 Brief profile Not Applicable (in case of appointment) 4 Disclosure of relationships Not Applicable between directors (in case of appointment of a director) Annexure B ENNATURE BIO PHARMA LIMITED (Formerly known as Ennature Bio Pharma Private Limited) Plot No. 2-B, Sector-126, Noida- 201304, Distt. Gautam Budh Nagar, Uttar Pradesh, Tel.: +91 120 3090100, 3090200, 6860000 Fax: +91 120 3090111, 30902111 E-mail: connect@ennature.com, Website: www.ennaturebiopharma.com 31.07.2026 India Glycols Limited Plot No. 2-B, Sector- 126, Noida-201304 Sub: Material update in connection with the Scheme of Arrangement amongst India Glycols Limited and Ennature Bio Pharma Limited (the Company) and IGL Spirits Limited and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Scheme"). Dear Sir/ Madam, This is to inform you that the Board of Directors of the Company, at its meeting held on July 31, 2026, has inter- alia, approved the appointment of Shri Akshay Bansal (DIN: 11836049) as an Additional Director (Executive Director) & Key Managerial Personnel, with effect from July 31, 2026. Further, subject to approval of the shareholders of the Company, his appointment as an executive Director shall be for a term of 5 (five) consecutive years commencing from July 31, 2026 till July 30, 2031. It is affirmed that Shri Akshay Bansal is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority in terms of BSE Circular LIST/COMP/14/2018-19 and NSE Circular NSE/CML/2018/24 dated June 20, 2018. Necessary details as required under Master Circular No. HO/49/14114(7)2025-CFD- POD2/]/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure A. This is for your information. Thanking You. Yours faithfully, For Ennatur J’fiharma Limited WV A WC ndra Pant irector DIN: 08850173 Encl: As above Registered Office: P.No. 4, Pharma City, Selaqui-248197, Dehradun, Uttarakhand, India Phone: +91 135-2698620, Fax: +91 135 2698939; CIN: U24290UR2021PLC013005 ENNATURE BIO PHARMA LIMITED (Formerly known as Ennature Bio Pharma Private Limited) Plot No. 2-B, Sector-126, Noida- 201304, Distt. Gautam Budh Nagar, Uttar Pradesh, Tel.: +91 120 3090100, 3090200, 6860000 Fax: +91 120 3090111, 30902111 E-mail: connect@ennature.com, Website: www.ennaturebiopharma.com Annexure-A S. No| Particulars Details 1 Reason for change | Shri Akshay Bansal (DIN: 11836049) has been appointed as Additional (appointment, Director (Executive Director) & Key Managerial Personnel resignation, removal, death or otherwise) 2 Date of July 31, 2026 for a period of 5 (five) years till July 30, 2031. appointment and term of appointment 3 Brief profile Shri Akshay Bansal aged 52 years is a seasoned leader with 26 years of experience across the pharmaceuticals, nutraceuticals, and nicotine industries. (in case of He has deep expertise in manufacturing operations, international commercial appointment) strategy, supply chain management, business development. He holds a graduate degree in Hospital Administration and a Master's degree in Business Administration (MBA) from Devi Ahilya University, Indore, and has completed a Certificate Programme in General Management (CPGM) from the Institute of Management Studies, Lucknow. Prior to his current appointment, he was serving as Head Sales & Marketing (Ennature Bio Pharma Division) of India Glycols Limited, the Holding Company. During his career, he has also worked with organizations such as Mankind Pharma Ltd., Glenmark Generics Ltd., Dishman Group, Alembic Pharmaceuticals Ltd. and Orchid Pharma. 4 Disclosure of Nil relationships between directors (in case of appointment of a director) Registered Office: P.No. 4, Pharma City, Selaqui-248197, Dehradun, Uttarakhand, India Phone: +91 135-2698620, Fax: +91 135 2698939; CIN: U24290UR2021PLC013005